Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Retained Earnings (2016 - 2025)

Amicus Therapeutics filings provide 16 years of Retained Earnings readings, the most recent being -$2.8 billion for Q4 2025.

  • On a quarterly basis, Retained Earnings fell 0.99% to -$2.8 billion in Q4 2025 year-over-year; TTM through Dec 2025 was -$2.8 billion, a 0.99% decrease, with the full-year FY2025 number at -$2.8 billion, down 0.99% from a year prior.
  • Retained Earnings hit -$2.8 billion in Q4 2025 for Amicus Therapeutics, roughly flat from -$2.8 billion in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$2.1 billion in Q1 2021 to a low of -$2.8 billion in Q1 2025.
  • Median Retained Earnings over the past 5 years was -$2.6 billion (2023), compared with a mean of -$2.6 billion.
  • Biggest five-year swings in Retained Earnings: fell 14.29% in 2022 and later fell 0.51% in 2025.
  • Amicus Therapeutics' Retained Earnings stood at -$2.3 billion in 2021, then fell by 10.3% to -$2.5 billion in 2022, then fell by 5.99% to -$2.7 billion in 2023, then dropped by 2.09% to -$2.7 billion in 2024, then dropped by 0.99% to -$2.8 billion in 2025.
  • The last three reported values for Retained Earnings were -$2.8 billion (Q4 2025), -$2.8 billion (Q3 2025), and -$2.8 billion (Q2 2025) per Business Quant data.